Valerio Therapeutics Société anonyme (EPA:ALVIO)

France · Delayed Price · Currency is EUR

0.7700

+0.0290 (3.91%)

Aug 3, 2026, 11:42 AM CET

1,067% (1Y)

Market Cap	370.09M +2,978.6%
Revenue (ttm)	2.57M +43.5%
Net Income	-4.90M
EPS	-0.02
Shares Out	499.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	352,716
Open	0.7400
Previous Close	0.7410
Day's Range	0.7400 - 0.7730
52-Week Range	0.0570 - 0.9800
Beta	1.80
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About EPA:ALVIO

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody– drug conjugates, and chimeric antigen receptors. The company was formerly known as... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1997

Employees 25

Stock Exchange Euronext Paris

Ticker Symbol ALVIO

Full Company Profile

Financial Performance

In 2025, EPA:ALVIO's revenue was 2.57 million, an increase of 43.50% compared to the previous year's 1.79 million. Losses were -4.90 million, -79.53% less than in 2024.

Financial Statements